🔎 Trials Near Me

Hjem › Kronisk lymfatisk leukæmi › Ohio › Columbus

Kronisk lymfatisk leukæmi kliniske forsøg i Columbus, OH

28 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i og omkring Columbus (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

RekruttererFase 3
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • Riverside Methodist Hospital, Columbus
  • og 8 flere
Alder 65 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • The Mark H Zangmeister Center, Columbus
  • og 8 flere
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

RekruttererFase 3
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04269902

Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 75 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07685717

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

RekruttererFase 2
  • The Ohio State University, Columbus
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

RekruttererFase 1/2
  • Research Site, Columbus
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT06564038

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

RekruttererFase 1
  • The James Cancer Hospital and Solove Research Institute, Columbus
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT05091424

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 31. aug. 2026 · NCT07734038

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

RekruttererFase 3
  • OSU Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT07342478

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RekruttererFase 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

RekruttererFase 1
  • The Ohio State University, Columbus
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06708897

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 12. jun. 2026 · NCT07271667

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

RekruttererFase 1
  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 2 og opefter · Alle køn · Opdateret 29. maj 2026 · NCT05418088

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

RekruttererFase 1
  • The Ohio State University, Columbus
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

RekruttererFase 4
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 2. mar. 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

RekruttererFase 4
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 2. mar. 2026 · NCT06876649

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 19. feb. 2026 · NCT06466122

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 19. feb. 2026 · NCT05336812

Study of SGR-1505 in Mature B-Cell Neoplasms

RekruttererFase 1
  • The Ohio State University - The James Cancer Hospital, Columbus
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

RekruttererFase 2
  • The Ohio State University /ID# 230439, Columbus
Alder 18 og opefter · Alle køn · Opdateret 9. feb. 2026 · NCT04895436

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 7. jan. 2026 · NCT05417165

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

RekruttererFase 2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 7. jan. 2026 · NCT06043674

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RekruttererFase 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 16. dec. 2025 · NCT06757647

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

RekruttererFase 1
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034

HPC Offered for PRESERVE Expansion

RekruttererObservationsstudie
  • The Ohio State University Medical Center, Columbus
Alder 12 til 80 · Alle køn · Opdateret 28. aug. 2025 · NCT07145411

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

RekruttererFase 1/2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2022 · NCT04502394

Kronisk lymfatisk leukæmi forsøg i andre byer

Andre studier i Columbus

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.